

# ProTrans presentation at Advanced Therapies Congress & Expo 2020

NextCell Pharma AB ("NextCell") has invited to present at the Advanced Therapies Congress & Expo 2020 which is the world's largest commercially focused ATMP event. Mathias Svahn, CEO, will present the ProTrans clinical trial results today at 12:30 CET.

NextCell has been invited to the ATMP event for the third year, an event that usually takes place in London in late May. However, this year due to the pandemic it is a virtual meeting as most of the congresses are. The presentation will not be publicly available but yesterdays webcast with principal investigator Professor Per-Ola Carlsson, Uppsala University and Uppsala University Hospital, Doctor Lindsay Davies, CSO NextCell and Karolinska Institutet and Doctor Mathias Svahn, CEO NextCell can be watch at: <https://youtu.be/HzV8T2kpdGI>

**For more information about NextCell Pharma AB, please contact:**

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Tel: 08-735 5595

E-mail: [info@nextcellpharma.com](mailto:info@nextcellpharma.com)

Hemsida: [www.nextcellpharma.com](http://www.nextcellpharma.com)

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

## About NextCell Pharma AB

NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.

FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, [info@fnca.se](mailto:info@fnca.se).